Nature Biotechnology 2004 - Abstracts
| Nature Biotechnology 2004 | |||||
| Title | Subject | Authors | |||
|---|---|---|---|---|---|
| 5'-end SAGE for the analysis of transcriptional start sites. | Business | Shin-ichi Hashimoto, Yutaka Suzuki, Yasuhiro Kasai, Kei Morohoshi, Tomoyuki Yamada, Jun Sese, Shinichi Morishita, Sumio Sugano, Kouji Matsushima | |||
| A bean counter's take on human resources. | Business | Paul Watson | |||
| A common open representation of mass spectrometry data and its application to proteomics research. | Business | Ruedi Aebersold, Stephen G. Oliver, Brian Raught, Jimmy K. Eng, Rolf Apweiler, Norman W. Paton, Patrick G.A. Pedrioli, Eric W. Deutsch, Sequin Huang, Keix Cheung, Eugene Kapp, Randall K. Julian Jr., Chris F. Taylor, Erik Nilsson, Richard Simpson, Robert Hubley, Brian Pratt, Mark E.X McComb, Mark E. McComb, Weimin Zhu, Gilbert Omenn, Ruth H. Angeletti, Richard Smith, Mathijs Vogelzang | |||
| A conditional marker gene allowing both positive and negative selection in plants. | Business | Torgny Nasholm, Oskar Erikson, Magnus Hertzberg | |||
| A cool way to make proteins. | Business | Catherine H. Schein | |||
| Adipose-derived adult stromal cells heal critical-size mouse calvarial defects. | Business | Michael T. Longaker, Catherine M. Cowan, Yun-Ying Shi, Oliver O Aalami, Yu-Fen Chou, Carina Mari, Benjamin Wu, Christopher H Contag, Natalina Quarto, Romy Thomas | |||
| Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. | Business | Tillman U. Gerngross | |||
| Agbiotech firms realign product focus. | Business | Jeffrey L Fox | |||
| Aggregation-resistant domain antibodies selected on phage by heat denaturation. | Business | Greg Winter, Laurent Jespers, . Oliver Schon, Kristoffer Famm | |||
| All systems go. | Business | Hannah Hoag | |||
| Alternative splicing in disease and therapy. | Business | Mariano A. Garcia-Blanco, Andrew P. Baraniak, Erika L. Lasda | |||
| A mightier mouse with human adaptive immunity. | Business | Marie H. Kosco-Vilbois | |||
| Analysis of genomic context: prediction of functional associations from conserved bidirectionally transcribed gene pairs. | Business | Peer Bork, Jan O. Korbel, Lars J. Jensen, Christian Von Mering | |||
| Analysis of the transcriptional complexity of Arabidopsis thaliana by massively parallel signature sequencing. | Business | Meyers, Blake C.; Vu, Tam H.; Tej, Shivakundan Singh, Ghazal, Hassan; Matvienko, Marta, Agrawal, Vikas; Ning, Jianchang, Christian D. Haudenschild | |||
| Analyzing antibody specificity with whole proteome microarrays. | Business | Hong Guo, Michael Snyder, Gregory A. Michaud, Michael Salcius, Barry I. Schweitzer, Rhonda Bangham, Fang Zhou, Paul Predki | |||
| A nanoliter-scale nucleic acid processor with parallel architecture. | Business | W. French Anderson, Jong Wook Hong, Vincent Studer, Gioa Hang, Stephen R Quake | |||
| An engineered epigenetic transgene switch in mammalian cells. | Business | Beat P. Kramer, Alessandro Usseglio Viretta, Marie Daoud-El Baba, Dominique Aubel, Wilfried Weber, Martin Fussenegger | |||
| A new harvest of fluorescent proteins. | Business | George H. Patterson | |||
| An image worth a thousand lives? | Business | Lisa A. Hammond, Sean X. Cavanaugh, Jr. Thomas Charles R. | |||
| An improved cyan fluorescent protein variant useful for FRET.(Forster resonance energy transfer ) | Business | Mark A Rizzo, Gerald H Springer, Butch Granada, David W Piston | |||
| Antibody-targeted cell fusion. | Business | Takafumi Nakamura, Kah-Whye Peng, Sompong Vongpunsawad, Mary Harvey, Hayakawa Takao, Hiroyuki Mizuguchi, Russell J. Stephen, Roberto Cattaneo | |||
| Antidote-mediated control of an anticoagulant aptamer in vivo. | Business | William P. Fay, Bruce A. Sullenger, Christopher P. Rusconi, Joseph D. Roberts, Shahid M. Nimjee, George Quick Jr., Geroge A. Pitoc, Rebekah R. White, Elizabeth Scardino | |||
| Antimicrobial drug discovery through bacteriophage genomics. | Business | Jing Liu, Jerry Pelletier, Philippe Gros, Dominique Bergeron, Nhuan Ha, Ramakrishnan Srikumar, Jinzi J Wu, Mohammed Dehbi, Greg Moeck, Francis Arhin, Pascale Buda, Mario Callejo, Vincent Ferretti, Tony Kwan, John McCarty, Dan Wiliams, Michael Dubow | |||
| Antisense and siRNA as agonists of Toll-like receptors. | Business | Sudhir Agarwal, Ekambar R. Kandimalla | |||
| A partnership between biology and engineering. | Business | Roger Brent | |||
| Apomixis technology development -- virgin births in farmers' fields? | Business | Ueli Grossniklaus, Charles Spillane, Mark D. Curtis | |||
| A proposed framework for the description of plant metabolomics experiments and their result. | Business | Stephen G. Oliver, Oliver Fiehn, Joachim Kopka, Douglas B. Kell, Jorn Smedsgaard, Geoffrey A. Lane, Pedro Mendes, Royston Goodacre, Robert Hall, Janet Taylor, Helen Jenkins, Nigel Hardy, Manfred Beckmann, John Draper, Aileen R. Smith, Raoul J. Bino, B. Markus Lange, Jang R. Liu, Basil J. Nikolau, Lloyd W. Sumner, Trevor Wang, Sean Walsh, Eve Syrkin Wurtele, Norman W. Paton, Sue Rhee, Ute Roessner-Tunali, Kazuki Saito | |||
| A regulatory patchwork-human ES cell research oversight. | Business | Lori P. Knowles | |||
| A role for chemistry in stem cell biology. | Business | Sheng Ding, Peter G Schultz | |||
| A simple method to cure established tumors by inflammatory killing of normal cells. | Business | Michael Gough, Alan Melcher, Gregory A. Daniels, Maoyi Lai, Luis Sanchez Perez, Kevin Harrington, Rosa Maria Diaz, Richard G. ile, Mahruz Karim, Timothy Kottke, Jill Thompsun, Andrew Bushell, Heung Chong | |||
| Ask the experts: how to get hired. | Business | Grace H.W. Wong | |||
| As products enter clinic... scientists shown the door. | Business | Mark Ratner | |||
| Assessing the survival of transgenic plant DNA in the human gastrointestinal tract. | Business | Trudy Netherwood, Anthony G O' Donnell, Julia Graham, Sally Gockling, John C. Mathers, Susana M. Martin-Orue, Gilbert Harry J. | |||
| Atazanavir sulphate. | Business | ||||
| A tethered catalysis, two-hybrid system to identify protein-protein interactions requiring post-translational modifications. | Business | Stanley Fields, Dawei Guo, Tony R. Hazbun, Xin-Jing Xu, Sze-Ling Ng, Min-Hao Kuo | |||
| A universal Tango? | Business | Vijay S. Pande | |||
| Australia experiments with 'experimental use' exemption. | Business | Amanda McBratney, Katherine Nielsen, Fiona McMillan | |||
| Baculovirus expression system for heterologous multiprotein complexes. | Business | Timothy J. Richmond, Imre Berger, Daniel J. Fitzgerald | |||
| Baculovirus solves a complex problem. | Business | Polly Roy | |||
| Beta-cell precursors-a work in progress. | Business | Gordon C. Weir, Susan Bonner Weir | |||
| Beyond the Petri dish. | Business | Shuguang Zhang | |||
| Biomaterials science and high-throughput screening. | Business | Jeffrey A. Hubbell | |||
| Bio-ontologies -- fast and furious. | Business | Judith Blake | |||
| Biotechnology financing dilemmas and the role of special purpose entities. | Business | Leora Schiff, Gloria Bevan | |||
| Bortezomib. | Business | ||||
| Breaching the skin's barrier to drugs. | Business | Brian W. Barry | |||
| Caged phosphopeptides reveal a temporal role for 14-3-3 in G1 arrest and S-phase checkpoint function. | Business | Michael B. Yaffe, Anhco Nguyen, Dborah M. Rothman, Justice Stehn, Barbara Imperiali | |||
| Cancer surgery joins the dots. | Business | Roger F. Uren | |||
| Can complexity be commercialized? | Business | George S. Mack | |||
| Capturing and profiling adult hair follicle stem cells. | Business | George Cotsarelis, Rebecca J. Morris, Yaping Liu, Lee Marles, Carol Trempus, Shulan Li, Jamie S. Lin, Janet A Sawicki | |||
| Changing talent needs to realize biotech products. | Business | Mary Ann Rafferty | |||
| Characterizing biological products and assessing comparability following manufacturing changes. | Business | Arthur J. Chirino, Anthony Mire-Sluis | |||
| Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor. | Business | Dal-Hee Min, Wei-Jen Tang, Milan Mrksich | |||
| Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation. | Business | Mark C. Fishman, Randall T. Peterson, Stanley Y. Shaw, Travis A. Peterson, David J. Milan, Tao P Zhong, Calum A MacRae, Stuart L Schreiber | |||
| Chile launches policy to boost biotech. | Business | Claudia Orellana | |||
| China approves first gene therapy.(Gendicine) | Business | Jeffrey F. Fox | |||
| Climbing the protein ladder. | Business | Norman J. Dovichi | |||
| Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages. | Business | Gregory Korbutt, Michael B. Wheeler, Raewyn.M. Seaberg, Simon R. Smukler, Timothy J. Kieffer, Derek Kooy | |||
| Cold-shock induced high-yield protein production in Escherichia coli. | Business | Mitsuhiko Ikura, Guoliang Qing, Masanori Mitta Takayama, Li-Chung Ma, Bing Xia, Ahmad Khorchid, Sangita Phadtare, G. V. T. Swapna, Haiping Ke, Tapas K. Mal, Gaetano T. Montelione, Masayori Inouye | |||
| Collaborative research presents special problems for patent seekers. | Business | Leigh W. Thorne, Edward R. Ergenzinger, W. Murray Spruill | |||
| Complete genome sequence of the metabolically versatile photosynthetic bacterium Rhodopseudomonas palustris. | Business | Caroline S. Harwood, Jane Gibson, Frank W. Larimer, Jane Lamerdin, Patrick Chain, Andrew S. Lang, Loren Hauser, Stephaine Malfatti, F Robert Tabita, Lon Do, Caroline Peres, Miriam L. Land, Janet L. Gibson, Faith H Harrison, Dale A. Pelletier, Thomas E. Hanson, J Thomas Beatty, Cedric Bobst, Torres y, Janelle L. Torres | |||
| Complete sequence and comparative genome analysis of the diary bacterium Streptococcus thermophilus. | Business | Alexander Bolotin, S. Dusko Ehrlich, Pierre Renault, Jean Delcour, Pascal Hols, Alla Lapidus, Michael Mazur, Eugene Goltsman, Michael Fonstein, Ross Overbeek, Andre Goffeau, Benoit Quinquis, Alexei Sorokin, Saulius Kulakauskas, Gordon D. Pusch, Nikos Kyprides, Benedicte Purnelle, Deborah Prozzi, Katrina Ngui, David Masuy, Frederic Hancy, Sophie Burteau, Marc Boutry | |||
| Computer security in academia -- a potential roadblock to distributed annotation of the human genome. | Business | Andrew Smith, Mark Gerstein, Michael Fischer, Dov Greenbaum, Shawn M. Douglas, Joanna Lim, Martin Schultz | |||
| Converting biotech scientists to managers. | Business | David G. Jensen, Eileen Dougherty | |||
| Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. | Business | Elio F. Vanin, Andrea L. Szymczak, Creg J. Workman, Yao Wang, Kate M. Vignali, Smaroula Dilioglou, Dario A. A. Vignali | |||
| Custom design of metabolism. | Business | James C Liao | |||
| Daniel Callahan.(bioethicists) | Business | Stephen Herrera | |||
| Daptomycin. | Business | ||||
| Data standards for 'omic' science. | Business | John Quackenbush | |||
| Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. | Business | Hans-Georg Rammensee, Stefan Stevanovic, Claudia Lemmel, Steffen Weik, Ute Eberle, Jorn Dengjel, Thomas Kratt, Horst-Dieter Becker | |||
| Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. | Business | Rakesh K. Jain, Lance L. Munn, David P. Ryan, Alan J. Fischman, David T. Scadden, Christopher G. Willett, Paul C. Shellito, Helen X. Chen, Dushyant V. Sahani, Gregory Y. Lauwers, Daniel C. Chung, Mari Mino, Sergey V. Kozin, Ricky T. Tong, Dan G. Duda, Sanjeeva P. Kalva, Alan C. Hartford, Kenneth S. Cohen, Lawrence S. Blaszkowsky, Boucher Yves, Emmanuelle Di Tomaso, Jeffery W. Clark, Andrew X. Zhu | |||
| Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. | Business | John R. Yates, Eberhard Durr, Karolina M. Krasinka, Phil Oh, Jan E. Schnitzer, Jingyi Yu, Lucy A. Carver, Jacqueline E. Testa | |||
| Discovery of transdermal penetration enhancers by high-throughput screening. | Business | Samir Mitragotri, Pankaj Karande, Amit Jain | |||
| DNA as a template for reaction discovery. | Business | Scott J. Miller | |||
| DNA vaccines-back in the saddle again? | Business | Kendall Powell | |||
| Do cloned mammals skip a reprogramming step?. | Business | Atsuo Ogura, Josef Fulka Jr., Norikazu Miyashita, Takashi Nagai | |||
| Does your chairman need to be a superma. | Business | Nicolas Hollanders | |||
| Drugs in crops-the unpalatable truth. | Business | ||||
| Editing the message from A to I. | Business | Kazuko Nishikura | |||
| Effecting a comprehensive intellectual property strategy using the Madrid protocol. | Business | William J. Simmons | |||
| Either/or selection markers for plant transformation. | Business | Ortrun Mittelsten Scheid | |||
| Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. | Business | Izhak Kehat, Oren Caspi, Rona Shofti, Irit Huber, Joseph Itskovitz-Eldor, Leonid Khimovich, Amira Gepstein, Gil Arbel, Jonathan Satin, Lior Gepstein | |||
| Embryonic stem cells pace the heart. | Business | Philippe Menasche | |||
| Encoded self-assembling chemical libraries. | Business | Samu Melkko, Jorg Scheuermann, Christoph E. Dumelin, Dario Neri | |||
| Enfuvirtide. | Business | ||||
| Engineered antibodies. | Business | Peter J. Hudson, Christelle Souriau | |||
| Engineered endophytic bacteria improve phytoremediation of water-soluble, volatile, organic pollutants. | Business | Daniel van der Lelie, Jaco Vangronsveld, Tanja Barac, Safiyh Taghavi, Brigitte Borremans, Ann Provoost, Licy Oeyen, Jan V. Colpaert | |||
| Engineered riboregulators enable post-transcriptional control of gene expression. | Business | Daniel J. Dwyer, Charles R. Cantor, Farren J. Isaacs, Chunming Ding, Dmitri D. Pervouchine, James J Collins | |||
| Engineered T-cell receptor tetramers bind MHC-peptide complexes with high affinity. | Business | Norman L. Letvin, Ramu A. Subbramanian, Kristi L. Martin, Akira Naoi, Darci A. Gorgone, Jorn E. Schmitz, Chikaya Motiya, Atsuhiko Hasegawa, Fred W. Peyerl, Patrick Attisier, Heng Chhay, Michelle A. Lifton, Kristine Kuus-Reichel, Marcelo J. Kuroda | |||
| Engineering plants with increased levels of the antioxidant chlorogenic acid. | Business | Ricarda Niggeweg, Anthony J. Michael, Cathie Martin | |||
| Engineering sweet targets for magic bullets. | Business | Ten Feizi | |||
| Enlightened receptor dynamics. | Business | Yosef Yarden, Gal Gur | |||
| Enzyme immobilization in a biomimetic silica support. | Business | Jim C. Spain, Rajesh R. Naik, Morley O. Stone, Heather R. Luckarift | |||
| EU expansion: enlarged horizons or false dawn?. | Business | Clare Sansom | |||
| Europe makes way into structural biology.(Partnership for Structural Biology) | Business | Sally Goodman | |||
| Evolution of a T7 RNA polymerase variant that transcribes 2'-o-methyl RNA. | Business | Andrew D. Ellington, Jijumon Chelliserrykattil | |||
| Ex planta phytoremediation of trichlorophenol and phenolic allelochemicals via an engineered secretory laccase. | Business | Guo-Dong Wang, Qian-Jin Li, Bin Luo, Xiao-Ya Chen | |||
| Exploiting biological complexity for strain improvement through systems biology. | Business | Gregory Stephanopoulos, Hal Alper, Joel Moxley | |||
| Expression profiling using a hexamer-based universal microarray. | Business | Matthew E Roth, Li Feng, Kevin J McConnell, Paul J Schaffer, Cesar E Guerra, Jason P Affourtit, Kevin R Piper, Lorri Guccione, Jayashree Hariharan, Maura J Ford, Stephen W Powell, Harish Krishnaswamy, Jennifer Lane, Lisa Guccione, Gino Intrieri, Jane S Merkel, Anthony Valerio, Clotilde Perbost, Carol D Graham, Brenda Zolla, Jonathan Hnath, Chris Michaelson, Rixin Wang, Conrad Halling, Baoge Ying, Craig E Parman, Debasish Raha, Ji Liao, Barbara Jedrzkiewicz, Brent Orr | |||
| FDA and EMEA pool scientific advice.(European Medicines Agency) | Business | Alla Katsnelson | |||
| Finding enzymatic gold on silver surfaces. | Business | Uwe T. Bornscheueer | |||
| Finding needles in haystacks. | Business | Jonathan A Javitch | |||
| Finding time for allosteric interactions. | Business | Irving W. Wainer | |||
| Fingerprinting the circulating repertoire of antibodies from cancer patients. | Business | Renata Pasqualini, Wadih Arap, Waun Ki Hong, Massimo Cristofanilli, Paul J. Mintz, Marco A. Arap, Patricia Troncoso, Jeri Kim, Christopher J. Logothetis, Kim-Anh Do | |||
| Flies in the soup - European GM labeling legislation. | Business | Neville Craddock | |||
| France to focus on few biotech clusters. | Business | Emilie Balcon | |||
| FRET between cardiac Na+ channel subunits measured with a confocal microscope and a streak camera.(Forster resonance energy transfer) | Business | Klaus Benndorf, Christoph Biskup, Thomas Zimmer | |||
| From alpha to omega -- producing essential fatty acids in plants. | Business | Allan G. Green | |||
| Functional proteomic screens reveal an essential extracellular role for hsp90alpha in cancer cells invasiveness. | Business | Len Neckers, Brenda K. Eustace, Dean Yimlamai, Blanca Lain, Gerald Beste, Leodevico Ilag, Takashi Sakurai, Jean K. Stewart, Christine Unger, Carol Zehetmeier, Claudia Torella, Stefan W. Henning, Bradley T. Scroggins, Daniel G. Jay | |||
| Funding high-throughput data sharing. | Business | Gavin Sherlock, Alvis Brazma, V Catherine A. Ball | |||
| Fusion proteins comprising a Fusarium-specific antibody linked to antifungal peptides protect plants against a fungal pathogen. | Business | Dieter Peschen, He-Ping Li, Fritz Kreuzaler, Rainer Fischer, Yu-Cai Liao | |||
| Gaining confidence in high-throughput protein interaction networks . | Business | Jonathan M. Rothberg, Joel S. Bader, Amitabha Chaudhuri, John Chant | |||
| Gas-inducible transgene expression in mammalian cells and mice. | Business | Dominique Aubel, Wilfried Weber, Martin Fussenegger, Markus Rimman, Manuela Spielmann, Bettina Keller, Marie Daoud-El baba, Cornelia C. Weber | |||
| Gefitinib. | Business | ||||
| Genentech discloses safety concerns over Avastin. | Business | Mark Ratner | |||
| Generation of a synthetic lymphoid tissue-like organoid in mice. | Business | Takeshi Watanabe, Sachiko Suematsu | |||
| Generation of marker-free plastid transformants using a transiently cointegrated selection gene. | Business | Sebastian M.J. Klaus, Fong-Chin Huang, Timothy J. Golds, Hans-Ulrich Koop | |||
| Generic expansion of the substrate spectrum of a DNA polymerase by directed evolution. | Business | Roger Woodgate, Shigenori Iwai, Francois Boudsocq, Farid J. Ghadessy, Anthony Brown, Philipp Holliger, David Loakes, Nicola Ramsay, Alexandra Vaisman | |||
| Genetic sequences: how are they patented? | Business | Guillaume Dufresne, Manuel Duval | |||
| Genome sequence of lignocellulose degrading fungus Phanerochaete chrysosporium strain RP78. | Business | Luis F. Larrondo, Dan Cullen, Bernard Henrissat, Jarrod Chapman, Diego Martinez, Nik Putnam, Maarten D. Sollewijn Gelpke, Katherine Huang, Kevin G. Helfenbein, Preethi Ramaiya, J. Chris Detter, Daniel Rokhsar, Randy Berka, Pedro M. Coutinho, Frank Larimer | |||
| Genomics companies shop around for chemical expertise. | Business | Liz Fletcher | |||
| Genomics taken to the extreme. | Business | Wolfgang Liebl | |||
| Genta sued over NDA withdrawal. | Business | George S. Mack | |||
| Germany reattempts to spark innovation. | Business | Martina Habeck | |||
| Goodbye Columbus! New NRDOs forego discovery. | Business | Karl A Thiel | |||
| Health biotechnology in China-reawakening of a giant. | Business | Halla Thorsteinsdottir, Uyen Quach, Li Zhenzhen, Zhang Jiuchun, Singer, Peter A.; Daar, Abdallah S. | |||
| High-affinity binders selected from designed ankyrin repeat protein libraries . | Business | Markus G. Grutter, Andreas Pluckthun, H. Kaspar Binz, Patrick Amstutz, Andreas Kohl, Michael T. Stumpp, Briand, Christophe;, Patrik Forrer | |||
| High-resolution genome-wide mapping of histone modifications. | Business | Keji Zhao, David Landsman, Tae-Young Roh, Wong Chi Ngau, Karrong Cui | |||
| High-throughout biochemistry heats up. | Business | Raymond F. Salemme | |||
| Homogenous detection of unamplified genomic DNA sequences based on colorimetric scatter of gold nanoparticle probes. | Business | James J. Storhoff, Adam D. Lucas, Viswanadham Garimella, Y. Paul Bao, Uwe R. Muller | |||
| Hsp90 invades the outside. | Business | Didier Picard | |||
| Humboldt University beefs up technology transfer. | Business | Martina Habeck | |||
| Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. | Business | Timothy Akhurst, Steven M. Larson, Peter M. Smith-Jones, David B. Solit, Neal Rosen | |||
| Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. | Business | Timothy Akhurst, Steven M. Larson, Peter M. Smith-Jones, David B. Solit, Neal Rosen, Farzana Afroze | |||
| Immunotherapy dispenses with tumor antigens. | Business | Soldano Ferrone | |||
| Immunotherapy: Past, present and future. | Business | Thomas A. Waldmann | |||
| Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. | Business | Roger Y. Tsien, Ben N.G. Giepmans, Nathan C. Shaner, Robert E. Campbell, Paul A. Steinbach, Amy E. Palmer | |||
| India aims to become the main bioinformatics hub. | Business | Sabine Louet, K. S. Jayaraman | |||
| India produces homegrown GM cotton.(Swarna Bharat Biotechnics Private) | Business | K.S. Jayaraman | |||
| Inhaled insulin products puff along. | Business | Kendall Powell | |||
| In silico simulation of biological network dynamics. | Business | David Eisenberg, Lukasz Salwinski | |||
| Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. | Business | Timothy R. Hughes, Charles Boone, Zhijian Li, Ainslie B. Parsons, Bilal Sheikh, Renee L. Brost, Grant W. Brown, Himing Ding, Patricia M. Kane, Chaoying Zhang | |||
| Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity. | Business | Tamar Morag-Sela, Ilan Cohn, Thomas J. Kowalski, Judy Jarecki-Black, Zoe Clyde-Watson | |||
| Intellectual property-the dispute between research institutions and voluntary health agencies. | Business | Marshall A Lichtman, Marjorie D Hunter, Gunta J Liders | |||
| Intensity-based protein identification by machine learning from a library of tandem mass spectra. | Business | Steven P. Gygi, Joshua E. Elias, Francis D. Gibbons, Oliver D. King, Frederick P. Roth | |||
| Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. | Business | John J. Rossi, Dong-Ho Kim, Michael Longo, Young Han, Patric Lundberg, Edouard Cantin | |||
| International benchmarking of biotech research centers-lessons and perspectives. | Business | Viola Peter | |||
| Introduction: Promoting global health through biotechnology. | Business | Douglas Martin, Peter A. Singer, Abdallah S. Daar, Halla Thorsteinsdottir, Uyen Quach | |||
| In vivo cancer targeting and imaging with semiconductor quantum dots. | Business | Xiaohu Gao, Shuming Nie, Yuanyuan Cui, Richard M. Levenson, Leland W. K. Chung | |||
| IPO plans sour on both sides of the pond.(initial public offering) | Business | ||||
| IPOs: The narrow window closes? | Business | Stacy Lawrence | |||
| Italian biotech too reliant on big pharma. | Business | Anna Meldolesi | |||
| Japanese firms broaden investment focus to early biotech. | Business | Sabine Louet, Doug Sipp | |||
| Japanese national universities are now 'incorporated'. | Business | Keiko Kandachi | |||
| Keeping dry and crossing membranes. | Business | Ariel Fernandez | |||
| Knockdown by RNAi-proceed with caution. | Business | Charles E. Samuel | |||
| Knocking the SOCS1 off dendritic cells.(suppressor of cytokine signaling-1) | Business | Eli Gilboa | |||
| Label-free detection becomes crystal clear. | Business | Paul S. Cremer | |||
| Lack of interferon response in animals to naked siRNAs.(small interfering ribonucleic acids) | Business | Jeremy D. Heidel, Siwen Hu, Xian Fang Liu, Timothy J. Triche, Davis Mark E. | |||
| Ligand selectivity and competition between enzymes in silico. | Business | A. Macchiarulo, Irene Nobeli | |||
| Make or break for costimulatory blockers. | Business | Ken Garber | |||
| Making prevention pay. | Business | Alan Dove | |||
| Managing innovation: university-industry partnerships and the licensing of the Harvard mouse. | Business | Sasha Blaug, Colleen Chien, Michael J. Shuster | |||
| Managing your compensation expectations in today's environment: a second look. | Business | John Radford | |||
| Mechanisms of gene silencing by double-stranded RNA. | Business | Thomas Tuschi, Gunter Meister | |||
| Memantine hydrochloride. | Business | ||||
| Microarray reality checks in the context of a complex disease. | Business | George L. Gabor Miklos, Ryszard Maleszka | |||
| Monitoring and modeling horizontal gene transfer. | Business | Kaare M. Nielson, Jeffrey P. Townsend | |||
| Moving in and out with quantum dots. | Business | Rakesh K. Jain, Mark Stroh | |||
| Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells. | Business | Robert Langer, Daniel G. Anderson, Shulamit Levenberg | |||
| Nanospheres for DNA separation chips. | Business | Mari Tabuchi, Noritada Kaji, Yukio Nagasaki; Kenichi Yoshikawa, Kazunori Kataoka, Yoshinoby Baba, Masanori Ueda, Yuichi Yamasaki | |||
| Navigating US conflict-of-interest rules when commercializing research. | Business | John Otrompke | |||
| Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. | Business | Akira Nakayama, Sungjee Kim, Lawrence H. Cohn, Young Taik Lim, Moungi G. Bawendi, J Anthony Parker, Edward G. Soltesz, John V Frangioni, Tomislav Mihaljevic, Alec M. De Grand, Rita G. Laurence, Lee, Jaihyoung; Dor, Delphine M. | |||
| Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. | Business | John J. Rossi, Hoshang J. Unwalla, Ming-Jie Li, James D. Kim, Hai Tang Li, Ali Ehsani, Jessica Alluin | |||
| New Zealand launches biotech seed fund. | Business | Kim Griggs | |||
| Next-generation protein drugs. | Business | Ian M. Tomlinson | |||
| NIH licensing performance under par.(National Institutes of Health) | Business | Ken Garber, Ann Arbor | |||
| Nuclear transfer cloning and the United Nations. | Business | Anthony CF Perry | |||
| Old dogma, new tricks-21st Century phage therapy. | Business | Karl Thiel | |||
| Oligo oligarchy -- the surprisingly small world of aptamers. | Business | Karl Thiel | |||
| Omalizumab. | Business | ||||
| On the road to therapeutic cloning. | Business | Teruhiko Wakayama | |||
| Overcoming the gridlock in discovery research. | Business | Jonathan Margolis, Greg D. Plowman | |||
| Para-position derivatives of fungal anthelmintic cyclodepsipeptides engineered with Streptomyces venezuelae antibiotic biosynthetic genes. | Business | Koji Yanai, Naomi Sumida, Kaoru Okakura, Tatsuki Moriya, Manabu Watanabe, Takeshi Murakami | |||
| Parent protection for protein structure analysis. | Business | Shigeyuki Yokoyama, Itsuki Shimbo, Rie Nakajima, Koichi Sumikura | |||
| Patent drop reveals pressures on industry. | Business | Stacy Lawrence | |||
| Patenting costs cast a shadow on European biotech. | Business | Peter Vermij | |||
| Paths to entrepreneurship in the life sciences. | Business | Shreefal Mehta | |||
| Phage-inspired antibiotics? | Business | Steven Projan | |||
| Phasing in iodine for structure determination. | Business | Zbigniew Dauter | |||
| Phosphoproteomics finds itEs timing. | Business | Tony Hunter, Sam A. Johnson | |||
| Photoswitchable cyan fluorescent protein for protein tracking. | Business | Vladislav V. Verkhusha, Dmitriy M. Chudakov, Dmitry B. Staroverov, Ekaterina A. Souslova, Sergey Lukyanov, Konstantin Lukyanov | |||
| Plant cell cultures for the production of recombinant proteins. | Business | Rainer Fischer, Stephen Hellwig, Jurgen Drossard, Richard M. Twyman | |||
| Polyvalent dendrimer glocosamine conjugates prevent scar tissue formation. | Business | Ian Teo, Sunil Shaunak, Sharyn Thomas, Elisabetta Gianasi, Antony Godwin, Emma Jones, Kamiar Mireskandari, Philip Luthert, Ruth Duncan, Steve Petterson, Pend Khaw, Steve Brocchini | |||
| Post-integration stabilization of a transposon vector by terminal sequence deletion in Drosophila melanogaster. | Business | Alfred .M. Handler, Grazyna .J. Zimowska, Carsten Horn | |||
| Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. | Business | Luis Serrano, Ana-Maria Fernandez-Escamilla, Frederic Rousseau, Joost Schymkowitz | |||
| Principles of transcriptional control in the metabolic network of Saccharomyces cerevisiae. | Business | Naama Barkai, Jan Ihmels, Ronen Levy | |||
| Proactive accounting: a key factor in the success of biotechnology startups. | Business | Christian Jester | |||
| Probing the precision of the mitotic clock with a live-cell fluorescent biosensor. | Business | Tobias Meyer, Joshua T. Jones, Jason W. Myers, James E. Ferrell Jr. | |||
| Problems in monitoring horizontal gene transfer in field trials of transgenic plants. | Business | Jack .A. Heinemann, Terje Traavik | |||
| Production of recombinant protein therapeutics in cultivated mammalian cells. | Business | Florian M. Wurm | |||
| Production of very long chain polyunsaturated omega-3 and omega-6 fatty acids in plants. | Business | Baoxiu Qi, Sam Mugford, Olga Sayanova, Colin M. Lazarus, Tom Fraser, Gary Dobson, A. Keith Stobart, Johnathan A. Napier, Justine Butler | |||
| Profiling epithelial stem cells. | Business | Paul A Khavari | |||
| Promoter prediction analysis on the whole human genome. | Business | Yutaka Suzuki, Sumio Sugano, Vladimir B. Bajic, Sin Lam Tan | |||
| Protecting methods for treatment related to regenerative medicine and gene therapy in Japan. | Business | Kiyofumi Kaneshiro, Sachika Masuda, Yayoi Tanaka, Katsuya Tamai | |||
| Protecting your investment. | Business | Harris F. Brotman | |||
| Protein interaction maps on the fly. | Business | Peter Uetz, Michael J. Pankratz | |||
| Protein sequencing by mass analysis of polypeptide ladders after controlled protein hydrolysis. | Business | Ying Zhang, Liang Li, Hongying Zhong, Zhihui Wen | |||
| Public biotechnology 2003 -- the numbers. | Business | Riku Lahteenmaki, Monya Baker | |||
| Public-private collaborations and the race to sequence Agrobacterium tumefaciens. | Business | Mark Harvey, Andrew McMeekin | |||
| Publish and perish: what constitutes a bar under the patent laws. | Business | Mark S. Cohen, Rachel Teitelbaum | |||
| Putting the opium in poppy to sleep. | Business | Johan Memelink | |||
| Putting the rat on the map. | Business | Ismail Kola | |||
| Quantitative analysis of allosteric drug-protein binding by biointeraction chromatography. | Business | Jianzhong Chen, David S. Hage | |||
| Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. | Business | Elizabeth A. Jares-Erijman, Thomas M. Jovin, Diane S Lidke, Rainer Heintzmann, Janine N Post, Peter Nagy, Donna J. Arndt-Jovin, Hernan E. Grecco | |||
| Rain or shine-a phototroph that delivers . | Business | Judy D. Wall | |||
| Rapid and ultra-sensitive determination of enzyme activities using surface-enhanced resonance Raman scattering. | Business | Lorna Stevenson, Chris Cassidy, Barry D. Moore, AlanWatt Watt Alan, Sabine Flitsch, Nicolas J. Turner, Duncan Graham | |||
| Rational siRNA design for RNA interference. | Business | Devin Leake, Anastasia Khvorova, Angela Reynolds, Queta Boese, Stephen Scaringe, William S. Marshall | |||
| Reality and immortality-neutral stem cells for therapies. | Business | Jeffrey D. Rothstein, Evan Y. Snyder | |||
| Recombinant protein folding and misfolding in Escherichia coli. | Business | Francois Baneyx, Mirna Mujacic | |||
| Recombinant protein therapeutics - success rates, market trends and values to 2010. | Business | Janice M. Reichert, Alex K. Pavlou | |||
| Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. | Business | Julie Johnson, Jonathan S. Draper, Kath Smith, Paul Gokhale, Harry D. Moore, Edna Maltby, Lorraine Meisner, Thomas P. Zwaka, James A. Thomson, Peter W. Andrews | |||
| Redesigner drugs. | Business | Alan Dove | |||
| Revealing the world of RNA interference. | Business | Craig C. Mello, Darryl Conte Jr. | |||
| Reversible site-selective labeling of membrane proteins in live cells. | Business | Emmanuel G Guignet, Ruud Hovius, Horst Vogel | |||
| Riding the risk cycle. | Business | Roop Chandwani, Simon Portman | |||
| RNAi-mediated replacement of morphine with the nonnarcotic alkaloid reticuline in opium poppy. | Business | Anthony J. Fist, Philip J. Larkin, Robert S. Allen, Anthony G. Millgate, Julie A. Chitty, Jennifer Thisleton, James A.C. Miller, Wayne R. Gerlach | |||
| RNA silencing in plants. | Business | David Baulcombe | |||
| Rosuvastatin calcium. | Business | ||||
| Russia becomes attractive as a source of IP for biotechs.(Intellectual property) | Business | Alla Katsnelson | |||
| Serial bull cloning by somatic cell nuclear transfer. | Business | Chikara Kubota, Cindy X. Tian, Xiangzhong Yang | |||
| Should software hold data hostage? | Business | George S. Michaels, H. Steven Wiley | |||
| Signal transduction inhibitors-a work in progress. | Business | Joseph Becker | |||
| Signal transduction inhibitors-a work in progress. | Business | Joseph Becker | |||
| Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity.(suppressor of cytokine signaling) | Business | Lei Shen, Kevin Evel-Kabler, Randy Strube, Si-Yi Chen | |||
| Singapore trains biotech workforce abroad. | Business | Jen Lin Liu | |||
| Single-chain antibodies against a plant viral RNA-dependent RNA polymerase confer virus resistance. | Business | KaJohn Boonrod, Danuta Galetzka, Peter D. Nagy, Udo Conrad, Gabi Krczal | |||
| South Africa-blazing a trail for African biotechnology. | Business | Douglas K. Martin, Halla Thorsteinsdottir, Uyen Quach, Marion Motari, Daar, Abdallah S.; Singer, Peter A. | |||
| Strategic HR for today's biotechnology companies. | Business | Mary Yaroshevsky Glanville | |||
| Streptococcal genomes provide food for thought. | Business | Herve Tettelin | |||
| Structure-aided drug design's next generation. | Business | Karl A. Thiel | |||
| Swiss patent proposal prompts criticism. | Business | Jane Burgermeister | |||
| Systematic identification of abundant A-to-I editing sites in the human transcriptome. | Business | Levanon, Erez Y.; Eisenberg, Esi; Yelin, Rodringo, Nemzer, Sergey; Hallegger, Martina; Shemesh, Ronen; Fligelman, Zipora; Shoshan, Avi, Pollocl, Sarah R.; Sztybel, Dan, Olshansky, Moshe; Rechavi, Gideon, Michael F. Jantsch | |||
| Systematic identification of sense-antisense transcripts in mammalian cells. | Business | Oystein Rosok, Mouldy Sioud | |||
| Systemic tumor targeting and killing by Sindbis viral vectors. | Business | Jen-Chieh Tseng, Daniel Meruelo, Maria Jimenez, Brandi Levin, Peter Shamamian, Alicia Hurtado, Ruzhong Jin, Yee, Herman,Novick, Richard P., Ignacio Perez de Castro, Angel Pellicer | |||
| Systems biology 101 - what you need to know. | Business | Trey Ideker | |||
| Systems biology in drug discovery. | Business | Eugene C. Butcher, Ellen L. Berg, Eric J. Kunkel | |||
| Tagging all genes. | Business | Jeffrey F. D. Dean | |||
| Teamwork in phytoremediation. | Business | Bernard R. Glick | |||
| Telomerase immortalization of neuronally restricted progenitor cells derived from the human fetal spinal cord. | Business | Maiken Nedergaard, Steven A. Goldman, Melissa K. Carpenter, H. Michael Keyoung, Neeta S. Roy, Jane Lin, Martha Windrem, Jian Kang, Takahiro Nakano, M. Lita Alonso, william K. Rashbaum, Weiguo Peng | |||
| Telomerase modulates expression growth-controlling genes and enhances cell proliferation. | Business | James M. Roberts, Laura L. Smith, Hilary A. Coller | |||
| Temperature-sensitive control of protein activity by conditionally splicing inteins. | Business | Norbert Perrimon, Yohanns Bellaiche, Martin P. Zeidler, Change Tan, Sara Cherry, Sabine Hader, Urte Gayko | |||
| Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics. | Business | Matthias Mann, Shao-En Ong, Blagoy Blagoev, Irina Kratchmarova | |||
| Ten thousand interactions for the molecular biologist. | Business | Robert B. Russell, Patrick Aloy | |||
| Term sheet trends in the venture capital market. | Business | Luci Staller Altman | |||
| Testing new ground. | Business | Hannah Hoag | |||
| The ABCs of artificial antigen presentation. | Business | Jean-Baptiste Latouche, Michel Sadelain, Isabelle Riviere, Jiyun V Kim | |||
| The best of both worlds in plant protection. | Business | Holger Bohlmann | |||
| The biological magic behind the bullets. | Business | Brent R. Stockwell | |||
| The Cartagena Protocol and the future of agbiotech. | Business | Willy De Greef | |||
| The challenges of modeling mammalian biocomplexity. | Business | Elaine Holmes, Ian D. Wilson, Jeremy K. Nicholson, John C. Lindon | |||
| The emergence of Egyptian biotechnology from generics. | Business | Peter A. Singer, Abdallah S. Daar, Halla Thorsteinsdottir, Uyen Quach, Basma Abdelgafar | |||
| The emerging role of academia in commercializing innovation. | Business | Shreefal Mehta | |||
| The evolution of molecular biology into systems biology. | Business | Hans V. Westerhoff, Bernhard O. Palsson | |||
| The exclusion of diagnostic methods from patentability by the EPC: a case for review?. | Business | Mathias Ricker | |||
| The fate of transgenes in the human gut. | Business | John Heritage | |||
| The functions of animal microRNAs. | Business | Victor Ambros | |||
| The genome sequence of the anaerobic, sulfate-reducing bacterium Desulfovibrio vulgaris Hildenborough. | Business | Ian T. Paulsen, Jonathan A. Eisen, John F. Heidelberg, William C. Nelson, Robert J. Dodson, Barbara Methe, Lauren M. Brinkac, Sean C. Daugherty, Rekha Seshadri, Shelley A. Haveman, Christopher L. Hemme, James F. Kolonay, Naomi Ward, Ramana Madupu, A. Scott Durkin, Robert T Deboy, Sullivan, Steven A.; Fouts, Derrick; Haft, Daniel H.; Selengut, Jeremy; Peterson, Jeremy D.; Davidsen, Tanja M.; Zafar, Nikhat; Zhou, Liwei;, Khouri, Hoda; Gill, John; Utterback, Terry R., Feldblyum, Tamara V.; Wall, Judy D.; Voordouw, Gerrit; Fraser, Claire M., Hance, Mark; Tran, Kevin, Radune, Diana; Dimitrov, George | |||
| The genome sequence of the capnophilic rumen bacterium Mannheimia succiniciproducens. | Business | Sang Yup Lee, Soon Ho Hong, Sun Shim Choi, Chang Hoon Kim, Cheol Goo Hur, Jin Sik Kim, Yong Ho In, Jeong-Keun Rih, Haeyoung Jeong, Jae Jong Kim | |||
| The genome sequence of the extreme thermophile Thermus thermophilus. | Business | Robert Huber, Anke Henne, Gerhard Gottschalk, Thomas Hartsch, Andre Johann, Arnim Wiezer, Carsten Raasch, Holger Bruggemann, Heiko Liesegang, Olivia Gohl, Tanja Lienard, Rosa Martinez-Arias, Vytaute Starkuviene, Carsten Jacobi, Silke Schlenczeck, Hans-Peter Klenk, Silke Dencker, Wilfried Kramer, Hans-Joachim Fritz, Rainer Merkl | |||
| The HUPO PSI's molecular interaction format-a community standard for the representation of protein interaction data.(Proteomics Standards Initiative )(Human Proteome Organization ) | Business | Alvis Brazma, Boris Steipe, David Eisenberg, Ioannis Xenarios, Akhilesh Pandey, Susan Moore, Peer Bork, Sylvain Poux, Marc Vidal, David Sherman, Chris Sander, Michael Lappe, Henning Hermjakob, Ugis Sarkans, Rong Zeng, Bernard Jacq, Luisa Montecchi-Palazzi, Gary Bader, Jerome Wojcik, Lukasz Salwinski, Arnaud Ceol, Sandra Orchard, Christian von Mering, Bernd Roechert, Eva Jung, Henning Mersch, Paul Kersey, Yixue Li, Debashis Rana, Macha Nikolski, Holger Husi, Christine Brun, K Shanker, Seth G N Grant, Weimin Zhu, Pierre Legrain, Gianni Cesarein, Chris Hogue, Rolf Apweiler | |||
| The impact of systems approaches on biological problems in drug discovery. | Business | Leroy Hood, Roger M. Perlmutter | |||
| The ins and outs of gene expression control. | Business | Francine B. Perler | |||
| The level of disclosure necessary for patent protection of genetic innovations. | Business | Richard J. Berman, Amy EL Schoenhard | |||
| The molecular properties and applications of Anthozoa fluorescent proteins and chromoproteins. | Business | Vladislav V. Verkhusha, Konstantin A. Lukyanov | |||
| The need for a public proteomics repository. | Business | Rong Wang, John T. Prince, Mark W. Carlson, Peng Lu, Edward M. Marcottem | |||
| The need for speed in stochastic simulation. | Business | Larry Lok | |||
| The plasma membrane-bound phospholipase D(delta) enhances freezing tolerance in Arabidopsis thaliana. | Business | Wenhua Zhang, Weiqi Li, Maoyin Li, Ruth Welti, Xuemin Wang | |||
| The prevalence of patent interferences in gene technology. | Business | Jon F. Merz, Michelle R. Henry | |||
| The pulse of mitosis. | Business | Conly L. Rieder, Alexei Mikhailov | |||
| The role of RNA interference in heterochromatic silencing. | Business | Rob Martienssen, Zachary Lippman | |||
| The site-specific incorporation of p-iodo-L-phenylalanine into proteins for structure determination. | Business | Peter G. Schultz, Lei Wang, Jianming Xie, Ning Wu, Ansgar Brock, Glen Spraggon | |||
| The use of nanocrystals in biological detection. | Business | Paul Alivisatos | |||
| Time-controlled transcardiac perfusion cross-linking for the study of protein interactions in complex tissues . | Business | Jian Yang, Stanley B. Prusiner, Stephen J. DeArmond, Fred E. Cohen, Gerold Schmitt-Ulms, Michael A. Baldwin, Cynthia Cowdrey, Jialing Liu, Kirk Hansen | |||
| Too little, too late: when is the right time for new leadership in biotech? | Business | Paul Branthwaite, Steven J. Williams | |||
| Towards quality assurance and harmonization of genetic testing services in the European Union. | Business | Dolores Ibarreta, Robert Elles, Emilio Rodriguez-Cerezo, Elisabeth Dequeker | |||
| Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation. | Business | Chunhui Xu, Yan Li, Ralph Brandenberger, Sally Zhang, Rixun Fang, Henry Wei, Gregory J. Fisk, Lawrence W. Stanton, Jane Lekowski, Ramumkar Mandalam, Mahendra S. Rao, Karl Guegler, Jaji Murage, Shirley Lei | |||
| Two-dimensional annotation of genomes. | Business | Bernhard Palsson | |||
| Uninhibited antibiotic target discovery via chemical genetics. | Business | Keith Poole | |||
| Unlocking the potential of the human genome with RNA interference. | Business | Gregory J. Hannon, John J. Rossi | |||
| Unnatural selection of cultured human ES cell?. | Business | Martin F. Pera | |||
| Unraveling protein interaction networks with near-optimal efficiency. | Business | Liisa Holm, Michael Lappe | |||
| Unshackling expression profiling arrays. | Business | Darrell P Chandler | |||
| US courts struggle with new patent infringement standards. | Business | Phill Jones | |||
| US food safety under siege? | Business | Richard Gilmore | |||
| US to safeguard 'dual-use' biology research. | Business | Jeffrey Fox L. | |||
| Valuation - what you need to know. | Business | Benoit Leleux, Patrik Frei | |||
| Valuing the product development cycle in agricultural biotechnology-what's in a name? | Business | David McElroy | |||
| Vardenafil hydrochloride and tadalafil. | Business | ||||
| Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. | Business | Werner Goebel, Yong A Yu, Tatyana M. Timiryasova, Chang Ch'ien, Ivaylo Gentschev, Aladar A. Szalay, Shahrokh Shabahang, Richard Beltz | |||
| What every CFO should know about equipment financing. | Business | J. Alden Philbrick | |||
| What is Bayesian statistics?. | Business | Sean R Eddy | |||
| What is dynamic programming? | Business | Sean R Eddy | |||
| What to expect at your biotech job interview. | Business | Mary Ann Rafferty | |||
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.